Skip to main content
. 2024;25(1):333–342. doi: 10.31557/APJCP.2024.25.1.333

Table 1.

Descriptive Statistics and Comparative Analysis of Patient Variables and Vital Status

Variable Levels Total (n=1873) Vital status P-value
Survived or discharged (n=1396) Deceased (n=492)
Age at diagnosis ----- 55.20 ± 14.55 54.82 ± 14.22 56.24 ± 15.43 0.064
Tumor size (cm) ----- 4.81 ± 3.11 4.71 ± 2.89 5.08 ± 3.65 0.023
Survival time ----- 23.98 (10.03, 40.39) 25.33 (9.81, 41.74) 19.37 (10.61, 35.08) <0.001
Hospital Taleghani 1127 (60.17) 889 (64.61) 236 (47.97) <0.001
Sari 219 (11.69) 111 (8.07) 108 (21.95)
Shiraz 527 (28.14) 376 (27.33) 148 (30.08)
Sex Male 1112 (59.37) 812 (59.01) 297 (60.37) 0.63
Female 761 (40.63) 564 (40.99) 195 (39.63)
Marital status Married 1777 (94.87) 1315 (95.57) 457 (92.89) 0.024
Other 96 (5.13) 61 (4.43) 35 (7.11)
BMI – four categories <18.5 140 (7.47) 80 (5.81) 58 (11.79) <0.001
18.6-24.9 1024 (54.67) 748 (54.36) 274 (55.69)
25-29.9 555 (29.63) 421 (30.60) 133 (27.03)
>30 154 (8.22) 127 (9.23) 27 (5.49)
BMI – three
categories
<18 145 (7.74) 83 (6.03) 60 (12.20) <0.001
18-25 1019 (54.40) 745 (54.14) 272 (55.28)
>25 709 (37.85) 548 (39.83) 160 (32.52)
Smoking No 1340 (71.54) 981 (71.29) 354 (71.95) 0.816
Yes 533 (28.46) 395 (28.71) 138 (28.05)
Education Illiterate 529 (28.24) 380 (27.62) 148 (30.08) 0.286
Primary school 614 (32.78) 459 (33.36) 153 (31.10)
High school 401 (21.41) 305 (22.17) 96 (19.51)
University 329 (17.57) 232 (16.86) 95 (19.31)
Hypertension No 1666 (88.95) 1216 (88.37) 447 (90.85) 0.153
Yes 207 (11.05) 160 (11.63) 45 (9.15)
Diabetes No 1684 (89.91) 1232 (89.53) 447 (90.85) 0.434
Yes 189 (10.09) 144 (10.47) 45 (9.15)
Familial history of cancer No 1208 (64.50) 865 (62.86) 338 (68.70) 0.021
Yes 665 (35.50) 511 (37.14) 154 (31.30)
Site topography Right colon 576 (30.75) 421 (30.60) 154 (31.30) 0.02
Left colon 1094 (58.41) 822 (59.74) 268 (54.47)
Rectum 183 (9.77) 122 (8.87) 61 (12.40)
Transverse 20 (1.07) 11 (0.80) 9 (1.83)
Grade Well differentiated 1042 (55.63) 819 (59.52) 221 (44.92) <0.001
Moderately differentiated 677 (36.15) 470 (34.16) 205 (41.67)
Poorly differentiated 154 (8.22) 87 (6.32) 66 (13.41)
Pathologic primary tumor T0 1074 (57.34) 837 (60.83) 232 (47.15) <0.001
T1 343 (18.31) 214 (15.55) 129 (26.22)
T2 143 (7.63) 113 (8.21) 30 (6.10)
T3 292 (15.59) 202 (14.68) 90 (18.29)
T4 21 (1.12) 10 (0.73) 11 (2.24)
Lymph node involved N0 924 (49.33) 731 (53.13) 191 (38.82) <0.001
N1 798 (42.61) 578 (42.01) 217 (44.11)
N2 151 (8.06) 67 (4.87) 84 (17.07)
Metastasis No 1091 (58.25) 857 (62.28) 230 (46.75) <0.001
Yes 284 (15.16) 148 (10.76) 136 (27.64)
Not known 498 (26.59) 371 (26.96) 126 (25.61)
Stage I 281 (15.00) 227 (16.50) 52 (10.57) <0.001
II 681 (36.36) 526 (38.23) 154 (31.30)
III 631 (33.69) 460 (33.43) 169 (34.35)
IV 280 (14.95) 163 (11.85) 117 (23.78)
Variable Levels Total (n=1873) Vital status P-value
Survived or discharged (n=1396) Deceased (n=492)
First treatment Surgery 1336 (71.33) 1051 (76.38) 281 (57.11) <0.001
Chemotherapy & Radiation Therapy & Immunotherapy 537 (28.67) 325 (23.62) 211 (42.89)
FAP No 1858 (99.20) 1363 (99.06) 490 (99.59) 0.379
Yes 15 (0.80) 13 (0.94) 2 (0.41)
HNPCC No 1705 (91.03) 1254 (91.13) 446 (90.65) 0.783
Yes 168 (8.97) 122 (8.87) 46 (9.35)
IBD No 1850 (98.77) 1361 (98.91) 484 (98.37) 0.347
Yes 23 (1.23) 15 (1.09) 8 (1.63)
Personal history of CRC No 1764 (94.18) 1296 (94.19) 464 (94.31) 1
Yes 109 (5.82) 80 (5.81) 28 (5.69)
Status Survived or discharged 1376 (73.47) 1376 (100.00) 0 (0.00) ------
Deceased 492 (26.27) 0 (0.00) 492 (100.00)
NA 5 (0.27) 0 0

Note: Descriptive statistics were reported in terms of frequency (%) for categorical data. Symmetric and asymmetric numeric data were expressed as mean ± standard deviation (SD) and median (interquartile range [IQR]), respectively. The relationship between categorical variables and vital status was investigated using the Fisher exact test. Additionally, the differences in symmetric and asymmetric variables between the deceased and survived groups were assessed using the independent t-test and Mann-Whitney U test, respectively.